J. Maxwell

发表

Photophysical characterization of 2,3-difunctionalized thieno[3,4-b]pyrazines

S. Rasmussen, D. Sattler, Kari A. Mitchell, 2004 .

New Antimalarial Trioxanes and Endoperoxides

G. Posner, M. Krasavin, P. Ploypradith, 2001 .

Inhibitors of hepatitis C virus NS3.4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokinetics.

M. Murcko, Chao Lin, R. Perni, 2007, Bioorganic & medicinal chemistry letters.

Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 proline variants.

M. Murcko, K. Wilson, B. G. Rao, 2004, Bioorganic & medicinal chemistry letters.

New synthetic methodology for ring expansion of n-sized conjugated cycloalkenones into homoallylic n+3 lactones: 3-step synthesis of fragrant phoracantholide ☆

G. Posner, J. Maxwell, J. S. Elias, 2000 .

In Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061

John R Fulghum, A. Kwong, B. G. Rao, 2004, Journal of Biological Chemistry.

Synthesis and evaluation of NS5A inhibitors containing diverse heteroaromatic cores.

L. Chan, S. Das, Oswy Z. Pereira, 2015, Bioorganic & medicinal chemistry letters.

Antimalarial sulfide, sulfone, and sulfonamide trioxanes.

T. Shapiro, G. Posner, M. Krasavin, 2000, Bioorganic & medicinal chemistry.

Mild, fast, and stereoselective epoxide opening by ketone enolate anions. Application to synthesis of the norlignan curculigine.

M. Kahraman, G. Posner, J. Maxwell, 2003, The Journal of organic chemistry.

Discovery of Thienoimidazole-Based HCV NS5A Genotype 1a and 1b Inhibitors.

L. Chan, S. Das, L. L'Heureux, 2014, ACS medicinal chemistry letters.

Abstract 3716: Potent radiation enhancement with VX-984, a selective DNA-PKcs inhibitor for the treatment of NSCLC

P. Charifson, W. Markland, D. Newsome, 2016 .

Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 2: non-symmetric inhibitors with potent activity against genotype 1a and 1b.

L. Chan, S. Das, L. L'Heureux, 2015, Bioorganic & medicinal chemistry letters.

Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 1: C2-symmetric inhibitors with diyne and biphenyl linkers.

L. Chan, S. Das, L. L'Heureux, 2015, Bioorganic & medicinal chemistry letters.

Benzimidazole-containing HCV NS5A inhibitors: effect of 4-substituted pyrrolidines in balancing genotype 1a and 1b potency.

L. Chan, S. Das, Oswy Z. Pereira, 2015, Bioorganic & medicinal chemistry letters.